Chemomab Therapeutics Ltd.
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$9.0M
- Total assets
- $13.8M
- Market cap
- $12.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating expenses
- $28.5M
- Income tax
- -$534.0K
- Net income
- -$27.6M
- EPS (basic)
- $0.12
- EPS (diluted)
- $0.12
Balance sheet
- Total assets
- $43.1M
- Current assets
- $41.7M
- Total liabilities
- $6.8M
- Current liabilities
- $6.7M
- Shareholders’ equity
- $36.2M
Cash flow
- Operating cash flow
- -$20.4M
- Investing cash flow
- $19.5M
- Financing cash flow
- -$808.0K
- Net cash flow
- -$1.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $12.7M
- P/E ratio
- 14.5
- EPS (diluted)
- $0.121
- Shares outstanding
- 7.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 17, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $9.0M.
- Trading 69% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 14.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Chemomab Therapeutics Ltd..
Write a review
News about Chemomab Therapeutics Ltd.
News & sentiment via Polygon.io
